Summary

Patients with locally advanced unresectable or metastatic soft tissue sarcoma have poor outcomes. Palliative chemotherapy is standard treatment for these patients, but it generally results in considerable toxicity. Previous studies have compared single-agent doxorubicin with doxorubicin plus ifosfamide, but the optimal doses remain unclear. This article discusses the European Organisation for Research and Treatment of Cancer 62012 Phase 3 study [NCT00061984] in patients with advanced soft tissue sarcoma.